Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma.
Journal
Cancer research communications
ISSN: 2767-9764
Titre abrégé: Cancer Res Commun
Pays: United States
ID NLM: 9918281580506676
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
25
10
2022
revised:
19
03
2023
accepted:
06
06
2023
medline:
11
7
2023
pubmed:
10
7
2023
entrez:
10
7
2023
Statut:
epublish
Résumé
Glioblastoma (GBM) is the most common and malignant primary brain tumor in adults. Immunotherapy may be promising for the treatment of some patients with GBM; however, there is a need for noninvasive neuroimaging techniques to predict immunotherapeutic responses. The effectiveness of most immunotherapeutic strategies requires T-cell activation. Therefore, we aimed to evaluate an early marker of T-cell activation, CD69, for its use as an imaging biomarker of response to immunotherapy for GBM. Herein, we performed CD69 immunostaining on human and mouse T cells following Immunotherapy may hold promise for the treatment of some patients with GBM. There is a need to assess therapy responsiveness to allow the continuation of effective treatment in responders and to avoid ineffective treatment with potential adverse effects in the nonresponders. We demonstrate that noninvasive PET/CT imaging of CD69 may allow early detection of immunotherapy responsiveness in patients with GBM.
Identifiants
pubmed: 37426447
doi: 10.1158/2767-9764.CRC-22-0434
pii: CRC-22-0434
pmc: PMC10324623
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1173-1188Subventions
Organisme : NCI NIH HHS
ID : R01 CA244520
Pays : United States
Organisme : NIBIB NIH HHS
ID : R21 EB029650
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA047904
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA214018
Pays : United States
Informations de copyright
© 2023 The Authors; Published by the American Association for Cancer Research.
Références
Int Immunol. 2018 Nov 14;30(12):559-567
pubmed: 30085193
Nat Med. 2019 Mar;25(3):477-486
pubmed: 30742122
Cancer Immunol Res. 2016 Feb;4(2):124-35
pubmed: 26546453
Cell. 2019 Aug 8;178(4):835-849.e21
pubmed: 31327527
Front Med (Lausanne). 2020 Feb 14;7:34
pubmed: 32118018
Bioconjug Chem. 2009 May 20;20(5):825-41
pubmed: 19125647
Nature. 2018 May;557(7706):575-579
pubmed: 29769722
J Autoimmun. 2014 Dec;55:51-62
pubmed: 24934597
Nat Commun. 2021 Nov 26;12(1):6938
pubmed: 34836966
Lancet Oncol. 2015 Nov;16(15):1473-1482
pubmed: 26482279
Nucl Med Biol. 2019 Apr;71:32-38
pubmed: 31128476
Mol Pharm. 2017 Mar 6;14(3):908-915
pubmed: 28191976
Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):343-9
pubmed: 23462419
Cancer Res. 2017 May 1;77(9):2318-2327
pubmed: 28461564
Proc Natl Acad Sci U S A. 2019 Jun 18;116(25):12410-12415
pubmed: 31152140
Lancet Oncol. 2015 Nov;16(15):e534-e542
pubmed: 26545842
Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1985-96
pubmed: 25053711
Clin Diagn Lab Immunol. 1996 May;3(3):301-4
pubmed: 8705673
Clin Cancer Res. 2021 Dec 1;27(23):6445-6456
pubmed: 34548318
J Clin Toxicol. 2014 Aug;4(4):
pubmed: 26539323
Clin Cancer Res. 2021 Feb 15;27(4):1058-1068
pubmed: 33087332
J Immunol Res. 2015;2015:497056
pubmed: 25759842
Cell Immunol. 1992 Jun;142(1):186-96
pubmed: 1586955
Br J Radiol. 2011 Dec;84 Spec No 2:S107-11
pubmed: 22433821
Cell Immunol. 2002 Nov;220(1):20-9
pubmed: 12718936
Int Immunol. 2004 Jun;16(6):799-809
pubmed: 15096475
Eur J Immunol. 2017 Jun;47(6):946-953
pubmed: 28475283
Curr Neurol Neurosci Rep. 2020 May 22;20(7):19
pubmed: 32445058
J Clin Invest. 2018 Jun 1;128(6):2569-2580
pubmed: 29596062
Am J Transl Res. 2020 May 15;12(5):1491-1514
pubmed: 32509158
Immunology. 1999 May;97(1):159-65
pubmed: 10447727
J Clin Invest. 2022 May 2;132(9):
pubmed: 35316223
Neuro Oncol. 2020 Oct 30;22(12 Suppl 2):iv1-iv96
pubmed: 33123732
Mol Imaging Biol. 2020 Jun;22(3):685-694
pubmed: 31529407
Nucl Med Biol. 2013 Jan;40(1):3-14
pubmed: 22998840
Clin Cancer Res. 2014 Oct 15;20(20):5290-301
pubmed: 24691018
Int Immunol. 2022 Oct 5;34(11):563-570
pubmed: 35460561
Cell Rep. 2017 Oct 31;21(5):1399-1410
pubmed: 29091775
Nature. 2006 Mar 23;440(7083):540-4
pubmed: 16525420
Mol Imaging Biol. 2017 Dec;19(6):903-914
pubmed: 28247187
Clin Cancer Res. 2007 Apr 1;13(7):2158-67
pubmed: 17404100
J Nucl Med. 1992 Nov;33(11):1972-80
pubmed: 1432158
Handb Clin Neurol. 2016;134:71-95
pubmed: 26948349
J Exp Med. 1994 Nov 1;180(5):1999-2004
pubmed: 7964477
Blood. 2018 Jan 4;131(1):39-48
pubmed: 29118006
J Exp Med. 2008 Sep 1;205(9):2125-38
pubmed: 18725522
J Neurooncol. 2015 Sep;124(2):207-14
pubmed: 26033546
JAMA. 2015 Dec 15;314(23):2535-43
pubmed: 26670971
Mol Cell Endocrinol. 2011 Mar 15;335(1):2-13
pubmed: 20398732
Clin Cancer Res. 2009 Dec 1;15(23):7412-20
pubmed: 19934295
EClinicalMedicine. 2021 Sep 16;41:101134
pubmed: 34585125
Curr Radiopharm. 2011 Apr;4(2):131-9
pubmed: 22191652
Clin Cancer Res. 2004 Oct 15;10(20):7063-70
pubmed: 15501986
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
Immunol Rev. 2017 Jul;278(1):87-100
pubmed: 28658550
Cancer Res. 2020 Jul 15;80(14):3023-3032
pubmed: 32156777
N Engl J Med. 2021 Mar 25;384(12):1168-1170
pubmed: 33761214
J Med Invest. 2007 Aug;54(3-4):195-9
pubmed: 17878667
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Nat Rev Immunol. 2020 Nov;20(11):651-668
pubmed: 32433532
J Transl Med. 2020 Dec 9;18(1):471
pubmed: 33298096
Immunity. 2020 May 19;52(5):825-841.e8
pubmed: 32396847
Clin Pharmacokinet. 2010 Aug;49(8):493-507
pubmed: 20608753
Cell Res. 2012 Mar;22(3):457-72
pubmed: 22357481
In Vivo. 2020 Jan-Feb;34(1):469-478
pubmed: 31882515
Nat Med. 2018 Dec;24(12):1852-1858
pubmed: 30478423
Blood. 2005 Jun 1;105(11):4399-406
pubmed: 15692061
Rheum Dis Clin North Am. 2017 Feb;43(1):65-78
pubmed: 27890174
Front Immunol. 2021 May 07;12:637146
pubmed: 34025646
Clin Exp Immunol. 2008 Mar;151(3):505-18
pubmed: 18234059
Front Oncol. 2021 Feb 09;11:620070
pubmed: 33634034
PLoS One. 2012;7(10):e48593
pubmed: 23119065
J Clin Med. 2021 Mar 26;10(7):
pubmed: 33810532
Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):11982-7
pubmed: 23818604
Int J Mol Sci. 2019 Oct 28;20(21):
pubmed: 31661771
Immunology. 1993 Oct;80(2):281-6
pubmed: 8262555
Oncoimmunology. 2018 Oct 16;8(1):e1525243
pubmed: 30546966
Biomed Res Int. 2014;2014:203601
pubmed: 24991539
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Cancer Res. 2019 Jul 1;79(13):3455-3465
pubmed: 31064845
Clin Transl Oncol. 2016 Nov;18(11):1062-1071
pubmed: 26960561
Stem Cells. 1994 Sep;12(5):456-65
pubmed: 7804122
Immunobiology. 2003;207(2):85-93
pubmed: 12675266
Neurooncol Adv. 2021 Jul 26;3(1):vdab100
pubmed: 34466804
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
Oncoimmunology. 2018 Sep 5;7(12):e1501137
pubmed: 30524896
Eur J Immunol. 2006 Oct;36(10):2632-8
pubmed: 16983725
Curr Treat Options Oncol. 2019 Feb 21;20(3):24
pubmed: 30790064
J Exp Med. 2003 May 5;197(9):1093-106
pubmed: 12732655
Cancer Immunol Res. 2022 Sep 1;10(9):1084-1094
pubmed: 35862229
Nat Protoc. 2010 Apr;5(4):739-43
pubmed: 20360768
J Immunol. 1989 Mar 15;142(6):1854-60
pubmed: 2466079
Theranostics. 2020 Jan 1;10(4):1708-1718
pubmed: 32042331
J Neurosci. 2013 Aug 28;33(35):14231-45
pubmed: 23986257